Live tape
Top 8, mentions 7d10,771GOOGL2,061 mentions▲ +0.04SNDK1,523 mentions▲ +0.11SPCX1,494 mentions▲ +0.08NBIS1,420 mentions▲ +0.09HTZ1,232 mentions▲ +0.10NVDA1,187 mentions▲ +0.08META1,015 mentions▲ +0.03MSFT839 mentions▲ +0.06

Equity · Healthcare

RYTM

Rhythm Pharmaceuticals, Inc. · NasdaqGM

$107 +0.94% 1D Finazon · prior-day close · Jul 17, 2026
Price · Chart
Our own end-of-day closes 40 sessions
$120 $80 20 May 17 Jul

The line runs $90.64 on 20 May through $107 on 17 July, on a scale from $80 to $120. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of RYTM over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 40 sessions over that window: $90.64 on 20 May 2026 through $107 on 17 July 2026.

Market cap $7.4B
52-week range $75.84 – $118
Avg volume 260.7K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Aug 18, 2026

RYTM insider trades

SEC Form 4 · last 90 days · newest reported trade 13 Aug 2026
Open-market buys 0
Open-market sells 4
Net sold $17.04M
Non-trade filings 3
Date Insider Type Shares Value
13 Aug 2026 Lee Jennifer Kayden EVP, Head of North America Sell 75,834 $8.90M
13 Aug 2026 Garfield Alastair Chief Scientific Officer Sell 7,763 $913K
13 Aug 2026 Shulman Joseph Chief Technical Officer Sell 5,079 $608K
12 Aug 2026 Mazabraud Yann EVP, Head of International Sell 57,000 $6.62M

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
13 Aug 2026 Lee Jennifer Kayden EVP, Head of North America Option exercise 56,601 $997K
13 Aug 2026 Shulman Joseph Chief Technical Officer Option exercise 2,024 $14K
12 Aug 2026 Mazabraud Yann EVP, Head of International Option exercise 46,625 $317K

RYTM reported financials

SEC EDGAR XBRL

RYTM reported revenue of $189.8M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$196.5M.

Figure Reported Period
Revenue $189.8M 31 Dec 2025 fiscal year
Net income −$196.5M 31 Dec 2025 fiscal year
Diluted EPS −$3.11 31 Dec 2025 fiscal year
Total assets $437.3M 30 Jun 2026 at period end
Total equity $103.0M 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

RYTM earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $-0.73 —
31 Mar 2026 Q1 2026 $-0.83 —
31 Dec 2025 FY 2025 $-3.11 —
30 Sep 2025 Q3 2025 $-0.82 —
30 Jun 2025 Q2 2025 $-0.75 —
31 Mar 2025 Q1 2025 $-0.81 —
31 Dec 2024 FY 2024 $-4.34 —
30 Sep 2024 Q3 2024 $-0.73 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

RYTM institutional holders

SEC Form 13F

12 of the 45 institutional funds we track reported a RYTM position for the quarter ended 30 Jun 2026 — a combined $892.4M; the latest of those filings landed 14 Aug 2026.

Fund Action Shares Value
Baker Bros. Advisors Held (±25%) 5,604,483 $622.3M
Citadel Advisors Held (±25%) −10.9% shares 1,263,652 $140.3M
Point72 Asset Management Trimmed −51.1% shares 414,210 $46.0M
Millennium Management Trimmed −29.9% shares 316,719 $35.2M
Duquesne Family Office New position 203,618 $22.6M
Renaissance Technologies Trimmed −73.5% shares 68,281 $7.6M
AQR Capital Management Held (±25%) −0.1% shares 59,208 $6.6M
Man Group Added +1,162.8% shares 50,788 $5.6M
D. E. Shaw & Co. Held (±25%) −7.6% shares 30,168 $3.3M
Tudor Investment Corp Trimmed −29.3% shares 13,886 $1.5M

Showing the 10 largest of 12 reported positions. The figures above count all of them.

Source: SEC EDGAR 13F filings

RYTM fails-to-deliver

SEC CNS data

On 31 Jul 2026, 11,125 shares of RYTM failed to deliver (about $1.2M) — the latest of 2 consecutive trading days with recorded fails.

Settlement date Shares failed Notional % of shares out
31 Jul 2026 11,125 $1.2M 0.016%
30 Jul 2026 68 $7K <0.001%
22 Jul 2026 527 $56K 0.001%
17 Jul 2026 328 $35K <0.001%
14 Jul 2026 4 $430 <0.001%

Source: SEC fails-to-deliver (CNS) data